Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert More >
Companies Commented On
Stephen G. Brozak is a top-ranked analyst in biotechnology, pharmaceuticals and medical devices according to the Starmine ranking system and The Wall Street Journal. He has worked in the securities industry for more than 25 years, where he held positions in sales, management, investment banking, and research analysis. He is now the Managing Partner and President of WBB Securities, an independent broker/dealer and full-service investment bank. Brozak holds a bachelor’s degree and a master’s degree in business administration from Columbia University. He is a retired lieutenant colonel in the United States Marine Corps and currently is a member of the Secretary of Navy's Retiree Council, advising on healthcare issues.
Do Away with the Pill-A-Day Biotech Model: Steve Brozak (2/6/14) The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new paradigm, in which budgets are restrained and companies generate curative therapies for unmet needs. In this interview with The Life Sciences Report, Brozak takes aim at a broken system and lists ten problem-solving companies that can adapt to the changes he believes must take place for healthcare to be profitable and productive. A bonus: These companies can also add vigor to investment portfolios.
Companies that Can Mend the Biotech Market: Stephen Brozak (4/11/13) Markets are not efficient—at least not in the short term. WBB Securities President Stephen Brozak admits to frustration when he sees small-cap companies with valuations that are disengaged from market realities. But Brozak's experience as a biotech investor, banker and analyst has taught him to be patient with these disconnection syndromes, and he now delights in prospects offered by select bargain-basement opportunities. In this interview with The Life Sciences Report, Brozak touches on 10 names that have been flying far below the radars of most investors.
Stephen Brozak: Changing the Way Money Is Made and Diseases Are Cured (1/24/13) Stephen Brozak doesn't mess around. He focuses on technologies poised to change the way medicine has been practiced for thousands of years. As president of WBB Securities, Brozak is talking to his clientele about revolutionary stem cell therapies that deal with disease in totally new ways. He's also bullish on new antibiotics—important innovations in a world facing a shortage of effective drugs and a potential crisis of catastrophic proportion. In this interview with The Life Sciences Report, Brozak talks up must-hear ideas that growth investors need to consider.
"NBS has crossed the 50% enrollment mark on its PreSERVE-AMI phase 2 clinical trial; safety looks good and enrollment should be completed this year." (4/11/13) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >